| Characteristics | NaCl + KCl NaCl only |
| Age at cancer diagnosis, mean (range) | 55 (31 - 71) 55 (31 - 78) |
| Gender (%) |
|
| Male | 8 (33%) 11 (42%) |
| Female | 16 (67%) 15 (58%) |
| Type of primary cancer (%) |
|
| Advanced gastric cancer | 5 (20%) 10 (38%) |
| Ovarian cancer | 3 (10%) 2 (7%) |
| Colon cancer | 4 (10%) 2 (7%) |
| Rectal cancer | 1 (3%) |
| Cervical cancer | 5 (20%) 1 (3%) |
| Appendiceal cancer | 1 (3%) |
| Endometrial cancer | 1 (4%) |
| Pancreatic cancer | 3 (10%) 5 (20%) |
| Uterine cancer | 1 (4%) 1 (3%) |
| Tonsilar cancer | 1 (4%) |
| Breast cancer | 1 (3%) |
| Salpinx cancer | 1 (3%) |
| lung cancer | 1 (4%) 1 (3%) |
| Klatskin tumor | 1 (4%) |
| Grade (%) |
|
| 3 | 9 (37%) 8 (30%) |
| 4 | 15 (63%) 18 (70%) |
| Karnofsky Performance Scale (%) |
|
| 80 - 100 | 15 (63%) 9 (39%) |
| 50 - 70 | 9 (37%) 16 (61%) |
| <50 | 0 (0%) |
| Treatment history |
|
| resection | 5 (20%) 9 (39%) |
| radiation therapy | 4 (20%) 2 (7%) |
| Cisplatin | 23 (95%) |
| Bevacizumab (Avastin), Ramucirumab, AI | 5 (20%) |
| Nivolumab | 2 (10%) |
| Abrexene | 1 (0.4%) 1 (3%) |
| 5-FU | 2 (10%) |
| Pembrolizmab | 2 (10%) |
| Padexol | 1 (4%) |
| Onbevzi | 1 (4%) |
| Gemcitabine | 1 (4%) |
| Taxotere, cyclophosphamide | 1 (4%) 4 (15%) |
| Capecitabine | 2 (7%) |
| FOLFOX, Opdivo (third generation), Xerox | 9 (39%) |